Stephane Kontos, Jeffrey Alan Hubbell
Poor pharmacokinetic profiles are often the underlying reason for the failure of novel protein drugs to reach clinical translation. Current passive half-life improvement methods focus on increasing the apparent hydrodynamic radius of the drug. We sought to ...
American Chemical Society2010